Cargando…
Open science versus commercialization: a modern research conflict?
BACKGROUND: Efforts to improve research outcomes have resulted in genomic researchers being confronted with complex and seemingly contradictory instructions about how to perform their tasks. Over the past decade, there has been increasing pressure on university researchers to commercialize their wor...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392762/ https://www.ncbi.nlm.nih.gov/pubmed/22369790 http://dx.doi.org/10.1186/gm316 |
_version_ | 1782237639998439424 |
---|---|
author | Caulfield, Timothy Harmon, Shawn HE Joly, Yann |
author_facet | Caulfield, Timothy Harmon, Shawn HE Joly, Yann |
author_sort | Caulfield, Timothy |
collection | PubMed |
description | BACKGROUND: Efforts to improve research outcomes have resulted in genomic researchers being confronted with complex and seemingly contradictory instructions about how to perform their tasks. Over the past decade, there has been increasing pressure on university researchers to commercialize their work. Concurrently, they are encouraged to collaborate, share data and disseminate new knowledge quickly (that is, to adopt an open science model) in order to foster scientific progress, meet humanitarian goals, and to maximize the impact of their research. DISCUSSION: We present selected guidelines from three countries (Canada, United States, and United Kingdom) situated at the forefront of genomics to illustrate this potential policy conflict. Examining the innovation ecosystem and the messages conveyed by the different policies surveyed, we further investigate the inconsistencies between open science and commercialization policies. SUMMARY: Commercialization and open science are not necessarily irreconcilable and could instead be envisioned as complementary elements of a more holistic innovation framework. Given the exploratory nature of our study, we wish to point out the need to gather additional evidence on the coexistence of open science and commercialization policies and on its impact, both positive and negative, on genomics academic research. |
format | Online Article Text |
id | pubmed-3392762 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-33927622012-07-11 Open science versus commercialization: a modern research conflict? Caulfield, Timothy Harmon, Shawn HE Joly, Yann Genome Med Open Debate BACKGROUND: Efforts to improve research outcomes have resulted in genomic researchers being confronted with complex and seemingly contradictory instructions about how to perform their tasks. Over the past decade, there has been increasing pressure on university researchers to commercialize their work. Concurrently, they are encouraged to collaborate, share data and disseminate new knowledge quickly (that is, to adopt an open science model) in order to foster scientific progress, meet humanitarian goals, and to maximize the impact of their research. DISCUSSION: We present selected guidelines from three countries (Canada, United States, and United Kingdom) situated at the forefront of genomics to illustrate this potential policy conflict. Examining the innovation ecosystem and the messages conveyed by the different policies surveyed, we further investigate the inconsistencies between open science and commercialization policies. SUMMARY: Commercialization and open science are not necessarily irreconcilable and could instead be envisioned as complementary elements of a more holistic innovation framework. Given the exploratory nature of our study, we wish to point out the need to gather additional evidence on the coexistence of open science and commercialization policies and on its impact, both positive and negative, on genomics academic research. BioMed Central 2012-02-27 /pmc/articles/PMC3392762/ /pubmed/22369790 http://dx.doi.org/10.1186/gm316 Text en Copyright ©2012 Caulfield et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Open Debate Caulfield, Timothy Harmon, Shawn HE Joly, Yann Open science versus commercialization: a modern research conflict? |
title | Open science versus commercialization: a modern research conflict? |
title_full | Open science versus commercialization: a modern research conflict? |
title_fullStr | Open science versus commercialization: a modern research conflict? |
title_full_unstemmed | Open science versus commercialization: a modern research conflict? |
title_short | Open science versus commercialization: a modern research conflict? |
title_sort | open science versus commercialization: a modern research conflict? |
topic | Open Debate |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392762/ https://www.ncbi.nlm.nih.gov/pubmed/22369790 http://dx.doi.org/10.1186/gm316 |
work_keys_str_mv | AT caulfieldtimothy openscienceversuscommercializationamodernresearchconflict AT harmonshawnhe openscienceversuscommercializationamodernresearchconflict AT jolyyann openscienceversuscommercializationamodernresearchconflict |